Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases

Clinical trial NCT07343479 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07343479
Sponsor: Zhejiang Cancer Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

NSCLC (Advanced Non-small Cell Lung Cancer)EGFR Gene Mutations Brain Metastasis

Start date: 2026-05-01
Primary completion: 2027-06-20
Enrollment: 45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.